**Dipak Datta, M.Sc. Ph.D.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Dipak Picture****Scientist E-I**Drug Target Discovery & DevelopmentCSIR-Central Drug Research InstituteSector 10, Jankipuram Extn., Sitapur RoadLucknow - 226031, UP, India**Link:**  **http://www.cdriindia.org/DipakDatta.html**

|  |  |
| --- | --- |
| Educational Qualifications | M.Sc. (1997) University of Burdwan, West Bengal.Ph.D. (2004) CNCI/Jadavpur University, Kolkata, West Bengal |
| E-Mail | dipak.datta@cdri.res.in |

 |
|   |
|  |
|   |
| **POSITIONS / EMPLOYMENT** |
|

|  |  |  |
| --- | --- | --- |
| • | 2004 -2010 | Postdoctoral Fellow, Division of Nephrology, Children’s Hospital Boston, Harvard Medical School, Boston, MA |
| • | 2010- 2011 | Instructor in Pathology, Harvard Medical School, Department of Pathology, BIDMC, Boston, MA. |
| • | 2011- Till Date | Scientist E-I, DTDD Division, CSIR-CDRI, Lucknow, UP, India |

 |
| **HONORS/AWARDS** |
|

|  |  |
| --- | --- |
| • | 1sT Class 1st Award in B.Sc - University of Burdwan |
| • | Young Investigator Award 2007 – American Transplant Society |
| • | Young Investigator Award 2010 – American Transplant Society |

 |
| **CURRENT AREAS OF INTEREST** |
|   |
|

|  |  |
| --- | --- |
| • | Chemokine Receptor Signaling in Cancer and vascular inflammation |
| • | Tumor Heterogeneity and Cancer Stem Cell Plasticity |

 |
|

|  |  |
| --- | --- |
|  • | Screening and mechanism of action of novel compounds/drugs for anticancer activity *in-vitro* and *in-vivo* |

 |
|  |
| **SELECTED ORIGINAL ARTICLES IN PEER-REVIEWED JOURNALS**1. Kanaujiya JK, Lochab S, Kapoor I, Pal P, **Datta D,** Bhatt ML, Sanyal S, Behre G, Trivedi AK. [Proteomic identification of Profilin1 as a co-repressor of Estrogen receptor alpha in MCF7 breast cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/23576398) Proteomics. 2013 Apr 10. doi: 10.1002/pmic.201200534. (Epub ahead of print) **(*JIF-4.50*)**
2. Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, Briscoe DM, **Datta D\*.** [Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.](http://www.ncbi.nlm.nih.gov/pubmed/22989616) Cytokine Growth Factor Rev. 2013, 24(1):41-9. (\*Corresponding Author) **(*JIF-8.83*)**
3. Banerjee P, Basu A, **Datta D**, Gasser M, Waaga-Gasser AM, Pal S. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. ***J Biol Chem***. 2011;286:33580-90. **(*JIF-5.8*)**
4. **Datta D**, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S. CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. ***J Biol Chem***. 2010;285:36842-8. **(*JIF-5.8*)**
5. Basu A, **Datta D**, Zurakowski D, Pal S. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. ***J Biol Chem***. 2010;285:25196-202. **(*JIF-5.8*)**
6. Edelbauer M, **Datta D**, Vos IH, Basu A, Stack MP, Reinders ME, et al. Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. ***Blood***. 2010;116:1980-9. **(*JIF-10.55*)**
7. Basu A#, Hoerning A#, **Datta D**, Edelbauer M, Stack MP, Calzadilla K, et al. **Cutting edge:** Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. ***J Immunol***. 2010;184:545-9. ( # Co-First Author) **(*JIF-5.78*)**
8. **Datta D**, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, et al. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. ***Cancer Res***. 2009;69:8902-9. **(*JIF-8.23*)**
9. Dormond O, Contreras AG, Meijer E, **Datta D**, Flynn E, Pal S, et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. ***J Immunol***. 2008;181:8088-95. **(*JIF-5.78*)**
10. **Datta D**, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. ***J Am Soc Nephrol***. 2008;19:2437-46. **(*JIF-9.66*)**
11. Basu A#, Contreras AG#, **Datta D**, Flynn E, Zeng L, Cohen HT, et al. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. ***Cancer Res***. 2008;68:5689-98. ( # Co-First Author) **(*JIF-8.23*)**
12. **Datta D**, Dormond O, Basu A, Briscoe DM, Pal S. Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. ***Am J Physiol Renal Physiol***. 2007;293:F1222-30. **(*JIF-3.8*)**
13. **Datta D**, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. ***Cancer Res***. 2006;66:9509-18. **(*JIF-8.23*)**
 |

**Current Lab Members:**

**Mr. Sanjeev Meena - Technical Assistant**

**Mr. Anup Kumar Singh, - CSIR JRF**

**Mr. Rakesh Kumar Arya - UGC JRF**

**Mr. Shrankhla Maheshwari - CSIR JRF**

**Mr. Akhilesh Singh - Senior Project Fellow**

**Dr. Uzma Shahab – Research Associate**